Latest Breaking News On - Dmitry rogachev national medical research center - Page 1 : comparemela.com

Illumina Granted Registration in Russia for Clinical NGS Platform, Reagents March 5, 2021 Illumina s NextSeq™ 550Dx next-generation sequencing (NGS) platform (pictured), associated reagent kits, and reagents for the company’s MiSeq™Dx have all been approved for use in Russia by the country’s medical device regulatory agency, Roszdravnadzor. [Illumina] Illumina said that its NextSeq 550Dx next-generation sequencing (NGS) platform, associated reagent kits, and reagents for the company’s MiSeq Dx have all been approved for use in Russia by the country’s medical device regulatory agency, Roszdravnadzor. Roszdravnadzor has granted medical device registration to NextSeq 550Dx, which Illumina launched in 2017 as its second FDA-regulated and CE-IVD marked clinical NGS system, with the goal of extending NGS to clinical labs.

Paula dowdyMikhail maschanTimofei rassokhinRospotrebnadzor russian agency for sanitaryDmitry rogachev national medical research centerMinistry of healthIndependent statesRussian agencySanitary controlSocial well beingEurope middle east asiaDirector generalPediatric hematologySenior vice presidentGeneral managerEurope middle east